We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > cytarabine

News List

VENCLEXTA, Low-Dose Cytarabine Combination Study for AML Does Not Meet Primary Endpoint americanpharmaceuticalreview
March 04, 2020
AbbVie announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA®) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with placebo did not meet its primary endpoint of ...
Global Patients Whining about the Production Suspension of the Cytarabine Manufacturer PharmaSources/Shanghai Xiaoyaoshi
July 01, 2019
Manufacturing delayed due to the manufacturer’s overhaul; production suspension leading to a shortage in the world
FDA Approves DAURISMO with Cytarabine for AML americanpharmaceuticalreview
December 28, 2018
he U.S. Food and Drug Administration (FDA) approved DAURISMO (glasdegib), in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in .....
Final NICE green light for Pfizer’s Mylotarg pharmatimes
November 19, 2018
Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine